Yoko Momonoi Celgene

Yoko joined Regulatory CMC at Celgene in March 2018 and works on a late phase CAR-T product.  Prior to Celgene, Yoko was at Novartis Pharmaceuticals where she was responsible for the initial process characterization of Kymriah.  Subsequently, in her role as Head of Late Stage Process Development at Novartis, she was responsible for the process development, process characterization, and comparability studies of late phase cell and gene therapy products.  Before joining the cell and gene therapy unit at Novartis, she was in Regulatory CMC at Novartis Japan where she gained broad regulatory experience in cell and gene therapy products, monoclonal antibodies, and small molecules.  She started her career in biotechnology at Genentech, where she worked on drug substance manufacturing site design and site startup as a process engineer.